The biotechnology sector in India is expected to achieve revenue of US$ 11.6 billion by 2017, growing at a compound annual growth rate (CAGR) of 22 per cent, according to a recent report by Ernst & Young (E&Y). The key growth drivers of the US$ 4.3 billion industry include strong domestic demand for biotech products, growth in contract services, focus on R&D initiatives and strong government support for the sector.
Revenue from biotech exports reached US$ 2.2 billion in FY13, accounting for more than half (51 per cent) of total industry revenues. During FY13, revenue from exports increased at a CAGR of 25.1 per cent to US$ 2.2 billion from US$ 0.4 billion. According to data released by the Department of Industrial Policy and Promotion (DIPP), the drugs and pharmaceuticals sector has attracted foreign direct investment (FDI) worth Rs 54,780.65 crore (US$ 8.81 billion) between April 2000 and September 2013.
The Indian Government's increased focus on the country's biotechnology industry has enabled it to grow at a CAGR of approximately 20 per cent over the past decade. With the growth in the customer base and more investments taking place in the biotech sector, the biotech industry is expected to grow to around Rs 440,000 crores (US$ 70.84 billion) by the year 2020. India has a share of over 2 per cent in the global biotechnology industry and is easily set to become one of the leading giants in the days to come.